Why This Massachusetts Synthetic Bio Startup Could be the Next Biotech Unicorn Post author:Sam Post published:December 11, 2017 Post category:BioPharma In investment jargon, a “unicorn” has at least two meanings. Source: BioSpace You Might Also Like Seattle’s PhaseRx Files for Bankruptcy as it Considers Partner, Merger or Sale Options December 10, 2017 The Verdict Is In: ConMed???s SurgiQuest Liable for $2.2 Million in Compensatory Damages April 11, 2017 Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. December 18, 2017
Seattle’s PhaseRx Files for Bankruptcy as it Considers Partner, Merger or Sale Options December 10, 2017
The Verdict Is In: ConMed???s SurgiQuest Liable for $2.2 Million in Compensatory Damages April 11, 2017
Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. December 18, 2017
